The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs)
has the potential to provide an unlimited source of insulin-producing β cells for the treatment …

Cell-based therapy holds great potential to address unmet medical needs and revolutionize
the healthcare industry, as demonstrated by several therapeutics such as CAR-T cell …

Insulin-producing β cells created from human pluripotent stem cells have potential as a
therapy for insulin-dependent diabetes, but human pluripotent stem cell-derived islets (SC …

Implantable drug delivery systems (IDDS) are an attractive alternative to conventional drug
administration routes. Oral and injectable drug administration are the most common routes …

Porosity is an important material feature commonly employed in implants and tissue
scaffolds. The presence of material voids permits the infiltration of cells, mechanical …

Diabetes involves the death or dysfunction of pancreatic β-cells. Analysis of bulk sequencing
from human samples and studies using in vitro and in vivo models suggest that endoplasmic …

Diabetes is a complex disease that affects over 400 million people worldwide. The life-long
insulin injections and continuous blood glucose monitoring required in type 1 diabetes …

Screening implantable biomaterials for antifibrotic properties is constrained by the need for
in vivo testing. Here we show that the throughput of in vivo screening can be increased by …

Intrahepatic islet transplantation is the standard cell therapy for β cell replacement. However,
the shortage of organ donors and an unsatisfactory engraftment limit its application to a …

Type 1 diabetes (T1D) is an autoimmune disease characterized by autoreactive T cell-
mediated destruction of insulin-producing pancreatic beta-cells. Loss of beta-cells leads to …